SOD1 and amyotrophic lateral sclerosis: Based on these promising results, Early Access Programs (EAPs) were initiated in various countries, and later tofersen for the treatment of SOD1-ALS was approved by the U.S. Food and Drug Administration (FDA) in April 2023.